Sign In
Buy NXL
$0.533
-0.0175 (-3.18%)
At Close: Jun 03, 2026
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
08:30am, Wednesday, 26'th Feb 2025
HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
08:30am, Tuesday, 18'th Feb 2025
HOUSTON, TX, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
09:00am, Monday, 10'th Feb 2025
HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of
HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23
11:00am, Thursday, 23'rd Jan 2025
HOUSTON, TX, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar today, January 23, 2025, a
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
10:00am, Monday, 23'rd Dec 2024
AI Components for Electronic Data Capture and Patient Monitoring to be Integrated into Phase 2 AI Components for Electronic Data Capture and Patient Monitoring to be Integrated into Phase 2
Report Highlights Nexalin's Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health Treatment Report Highlights Nexalin's Unique Non-Invasive Solution
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th
02:00pm, Friday, 01'st Nov 2024
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on November 5, 2024, at 4:
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
10:34am, Friday, 01'st Nov 2024
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Marke
LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 01'st Nov 2024
ORLANDO, FL / ACCESSWIRE / November 1, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (Nasdaq:LOBO) and Nexalin Technology, Inc. (Nasdaq:NXL) on the RedChip Small Stocks,
New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Pat
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 25'th Oct 2024
ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Smal
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
02:15pm, Tuesday, 22'nd Oct 2024
Gen-3 Halo Headset Designed to Offer Convenient At-Home Treatment Through Virtual Clinic Model Study to Build on Positive Results from Previous Clinical Trial Treating Veterans with Mild Traumatic Bra
Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer's Treatment Groundbreaking Trial Reveals DIFS Increases Neural Activity and B
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
08:30am, Monday, 14'th Oct 2024
Veteran medical device executive to drive regulatory and clinical strategy as Nexalin advances drug-free Deep Intracranial Frequency Stimulation (DIFS) technology for mental health treatment Veteran m
